HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF
The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | CHO TOO-HYON PARK MI-HEE PARK YOUNG-WOO YOO HYEON-MI LEE DONG-SUP PYUN BO-JEONG KIM SEMI YUN CHAE-OK KOH SANG-SEOK KIM DO-YUN JEON JAE-WON SHIM SANG-RYEOL LEE DONG-HEON JANG HYUN-SOOK KANG JEONG-EUN SUL SAM-SOOK LEE WEON-SUP KIM SUNG-WOO KWON YOUNG-GUEN RHA GEUN-BAE KIM NAHM-JU LEE JOONUL YOO JIN-SAN KIM KWI-HWA |
| description | The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2014288274A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2014288274A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2014288274A13</originalsourceid><addsrcrecordid>eNqNyrEKwjAQgOEuDqK-w4GzYGvBrmd6bQLxTtJE0aVUiZNoob4_VvABnP5_-KbJVYc9MuyFRVlhtIDszU7KMzAF79Cai-EajtioYNEBcSlekzUjrZ2cvIYKlRcHjhQdvoNcQmgIRuZIqnkyuXePIS5-nSXLirzSq9i_2jj03S0-47sNTbZO86wosm2O6eY_9QH9JjVf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF</title><source>esp@cenet</source><creator>CHO TOO-HYON ; PARK MI-HEE ; PARK YOUNG-WOO ; YOO HYEON-MI ; LEE DONG-SUP ; PYUN BO-JEONG ; KIM SEMI ; YUN CHAE-OK ; KOH SANG-SEOK ; KIM DO-YUN ; JEON JAE-WON ; SHIM SANG-RYEOL ; LEE DONG-HEON ; JANG HYUN-SOOK ; KANG JEONG-EUN ; SUL SAM-SOOK ; LEE WEON-SUP ; KIM SUNG-WOO ; KWON YOUNG-GUEN ; RHA GEUN-BAE ; KIM NAHM-JU ; LEE JOONUL ; YOO JIN-SAN ; KIM KWI-HWA</creator><creatorcontrib>CHO TOO-HYON ; PARK MI-HEE ; PARK YOUNG-WOO ; YOO HYEON-MI ; LEE DONG-SUP ; PYUN BO-JEONG ; KIM SEMI ; YUN CHAE-OK ; KOH SANG-SEOK ; KIM DO-YUN ; JEON JAE-WON ; SHIM SANG-RYEOL ; LEE DONG-HEON ; JANG HYUN-SOOK ; KANG JEONG-EUN ; SUL SAM-SOOK ; LEE WEON-SUP ; KIM SUNG-WOO ; KWON YOUNG-GUEN ; RHA GEUN-BAE ; KIM NAHM-JU ; LEE JOONUL ; YOO JIN-SAN ; KIM KWI-HWA</creatorcontrib><description>The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.</description><language>eng</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2014</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140925&DB=EPODOC&CC=US&NR=2014288274A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140925&DB=EPODOC&CC=US&NR=2014288274A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHO TOO-HYON</creatorcontrib><creatorcontrib>PARK MI-HEE</creatorcontrib><creatorcontrib>PARK YOUNG-WOO</creatorcontrib><creatorcontrib>YOO HYEON-MI</creatorcontrib><creatorcontrib>LEE DONG-SUP</creatorcontrib><creatorcontrib>PYUN BO-JEONG</creatorcontrib><creatorcontrib>KIM SEMI</creatorcontrib><creatorcontrib>YUN CHAE-OK</creatorcontrib><creatorcontrib>KOH SANG-SEOK</creatorcontrib><creatorcontrib>KIM DO-YUN</creatorcontrib><creatorcontrib>JEON JAE-WON</creatorcontrib><creatorcontrib>SHIM SANG-RYEOL</creatorcontrib><creatorcontrib>LEE DONG-HEON</creatorcontrib><creatorcontrib>JANG HYUN-SOOK</creatorcontrib><creatorcontrib>KANG JEONG-EUN</creatorcontrib><creatorcontrib>SUL SAM-SOOK</creatorcontrib><creatorcontrib>LEE WEON-SUP</creatorcontrib><creatorcontrib>KIM SUNG-WOO</creatorcontrib><creatorcontrib>KWON YOUNG-GUEN</creatorcontrib><creatorcontrib>RHA GEUN-BAE</creatorcontrib><creatorcontrib>KIM NAHM-JU</creatorcontrib><creatorcontrib>LEE JOONUL</creatorcontrib><creatorcontrib>YOO JIN-SAN</creatorcontrib><creatorcontrib>KIM KWI-HWA</creatorcontrib><title>HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF</title><description>The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2014</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAQgOEuDqK-w4GzYGvBrmd6bQLxTtJE0aVUiZNoob4_VvABnP5_-KbJVYc9MuyFRVlhtIDszU7KMzAF79Cai-EajtioYNEBcSlekzUjrZ2cvIYKlRcHjhQdvoNcQmgIRuZIqnkyuXePIS5-nSXLirzSq9i_2jj03S0-47sNTbZO86wosm2O6eY_9QH9JjVf</recordid><startdate>20140925</startdate><enddate>20140925</enddate><creator>CHO TOO-HYON</creator><creator>PARK MI-HEE</creator><creator>PARK YOUNG-WOO</creator><creator>YOO HYEON-MI</creator><creator>LEE DONG-SUP</creator><creator>PYUN BO-JEONG</creator><creator>KIM SEMI</creator><creator>YUN CHAE-OK</creator><creator>KOH SANG-SEOK</creator><creator>KIM DO-YUN</creator><creator>JEON JAE-WON</creator><creator>SHIM SANG-RYEOL</creator><creator>LEE DONG-HEON</creator><creator>JANG HYUN-SOOK</creator><creator>KANG JEONG-EUN</creator><creator>SUL SAM-SOOK</creator><creator>LEE WEON-SUP</creator><creator>KIM SUNG-WOO</creator><creator>KWON YOUNG-GUEN</creator><creator>RHA GEUN-BAE</creator><creator>KIM NAHM-JU</creator><creator>LEE JOONUL</creator><creator>YOO JIN-SAN</creator><creator>KIM KWI-HWA</creator><scope>EVB</scope></search><sort><creationdate>20140925</creationdate><title>HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF</title><author>CHO TOO-HYON ; PARK MI-HEE ; PARK YOUNG-WOO ; YOO HYEON-MI ; LEE DONG-SUP ; PYUN BO-JEONG ; KIM SEMI ; YUN CHAE-OK ; KOH SANG-SEOK ; KIM DO-YUN ; JEON JAE-WON ; SHIM SANG-RYEOL ; LEE DONG-HEON ; JANG HYUN-SOOK ; KANG JEONG-EUN ; SUL SAM-SOOK ; LEE WEON-SUP ; KIM SUNG-WOO ; KWON YOUNG-GUEN ; RHA GEUN-BAE ; KIM NAHM-JU ; LEE JOONUL ; YOO JIN-SAN ; KIM KWI-HWA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2014288274A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2014</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>CHO TOO-HYON</creatorcontrib><creatorcontrib>PARK MI-HEE</creatorcontrib><creatorcontrib>PARK YOUNG-WOO</creatorcontrib><creatorcontrib>YOO HYEON-MI</creatorcontrib><creatorcontrib>LEE DONG-SUP</creatorcontrib><creatorcontrib>PYUN BO-JEONG</creatorcontrib><creatorcontrib>KIM SEMI</creatorcontrib><creatorcontrib>YUN CHAE-OK</creatorcontrib><creatorcontrib>KOH SANG-SEOK</creatorcontrib><creatorcontrib>KIM DO-YUN</creatorcontrib><creatorcontrib>JEON JAE-WON</creatorcontrib><creatorcontrib>SHIM SANG-RYEOL</creatorcontrib><creatorcontrib>LEE DONG-HEON</creatorcontrib><creatorcontrib>JANG HYUN-SOOK</creatorcontrib><creatorcontrib>KANG JEONG-EUN</creatorcontrib><creatorcontrib>SUL SAM-SOOK</creatorcontrib><creatorcontrib>LEE WEON-SUP</creatorcontrib><creatorcontrib>KIM SUNG-WOO</creatorcontrib><creatorcontrib>KWON YOUNG-GUEN</creatorcontrib><creatorcontrib>RHA GEUN-BAE</creatorcontrib><creatorcontrib>KIM NAHM-JU</creatorcontrib><creatorcontrib>LEE JOONUL</creatorcontrib><creatorcontrib>YOO JIN-SAN</creatorcontrib><creatorcontrib>KIM KWI-HWA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHO TOO-HYON</au><au>PARK MI-HEE</au><au>PARK YOUNG-WOO</au><au>YOO HYEON-MI</au><au>LEE DONG-SUP</au><au>PYUN BO-JEONG</au><au>KIM SEMI</au><au>YUN CHAE-OK</au><au>KOH SANG-SEOK</au><au>KIM DO-YUN</au><au>JEON JAE-WON</au><au>SHIM SANG-RYEOL</au><au>LEE DONG-HEON</au><au>JANG HYUN-SOOK</au><au>KANG JEONG-EUN</au><au>SUL SAM-SOOK</au><au>LEE WEON-SUP</au><au>KIM SUNG-WOO</au><au>KWON YOUNG-GUEN</au><au>RHA GEUN-BAE</au><au>KIM NAHM-JU</au><au>LEE JOONUL</au><au>YOO JIN-SAN</au><au>KIM KWI-HWA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF</title><date>2014-09-25</date><risdate>2014</risdate><abstract>The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2014288274A1 |
| source | esp@cenet |
| subjects | CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES |
| title | HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T09%3A18%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHO%20TOO-HYON&rft.date=2014-09-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2014288274A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |